Chinook Therapeutics (KDNY) Stock Price, News & Analysis

11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Chinook Therapeutics in the last twelve months. There are currently 10 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" KDNY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KDNY, but not buy additional shares or sell existing shares.
View KDNY analyst ratings or view top-rated stocks.

11 equities research analysts have issued 12-month price targets for Chinook Therapeutics' stock. Their KDNY share price targets range from $32.00 to $42.00. On average, they predict the company's stock price to reach $37.25 in the next year. This suggests that the stock has a possible downside of 7.8%.
View analysts price targets for KDNY or view top-rated stocks among Wall Street analysts.

Chinook Therapeutics, Inc. (NASDAQ:KDNY) released its quarterly earnings data on Tuesday, May, 9th. The company reported ($0.85) earnings per share for the quarter, missing analysts' consensus estimates of ($0.82) by $0.03. The company had revenue of $1.83 million for the quarter, compared to the consensus estimate of $0.14 million. Chinook Therapeutics had a negative net margin of 4,199.93% and a negative trailing twelve-month return on equity of 58.28%. The firm's revenue was down 32.2% compared to the same quarter last year.

ETFs with the largest weight of Chinook Therapeutics (NASDAQ:KDNY) stock in their portfolio include AltShares Merger Arbitrage ETF (ARB) and SPDR S&P Biotech ETF (XBI).Principal Healthcare Innovators ETF (BTEC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Chinook Therapeutics investors own include BioSyent (RX) and Continental Resources (CLR).